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ABSTRACT
Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib 
with chemotherapy and radiotherapy treatment in a variety of cancer increasing 
the therapeutic ratio for olaparib may come from its ability to modify the tumour 
microenvironment by targeting homologous recombination-deficient, hypoxic tumour 
clonogens, and/or increasing tumour-associated vasodilation to improve oxygenation. 
Herein, we investigated the effect of prolonged neoadjuvant exposure to olaparib on 
the tumor microenvironment using a genetically-engineered mouse p53-/- syngeneic 
breast cancer model, which is proficient in homology-directed DNA repair. We 
observed increased in vivo growth delay and decreased ex vivo clonogenic survival 
following pre-treatment with olaparib 50 mg/kg bid Olaparib for 7 days ending 48 
hours prior to a radiation dose of 12Gy. This increased in vivo radioresponse was 
associated with a decreased hypoxic fraction. This study suggests that the radiation 
response in patients can be improved with limited toxicity if olaparib is given in a 
purely neoadjuvant setting to modify the tumor microenviroment prior to the start 
of the radiotherapy treatment. Consequently a significant gain can be achieved in 
therapeutic window and clinical studies are needed to confirm this preclinical data.
INTRODUCTION
Majority of the cancer patients undergo radiation 
therapy as a primary or adjuvant treatment for their cancers 
but may fail due to tumour clonogen radioresistance 
leading to poor local control and secondary metastases. 
Tumour specific inhibition of the DNA damage response 
pathway and targeting intratumoural hypoxia are two 
attractive strategies designed to improve the radiation 
response [1, 2]. PARP-1 inhibitors are of specific interest 
because they target the DNA repair pathway and they may 
also have an effect on the tumor vasculature [3-7]. PARP-1 
inhibitors are now FDA-approved for advanced hereditary 
BRCA-mutated ovarian cancers given their ability to kill 
homologous recombination repair (HRR)-deficient tumour 
cells by synthetic lethality. Olaparib (AZD2281) is a 
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potent inhibitor of PARP-1 and is currently being tested 
in the clinic in combination with radiotherapy for many 
tumor indications (breast, lung, prostate, pancreatic and 
head & neck cancers) [8]. PARP-1 is involved in many 
cellular processes (e.g. DNA repair, genomic stability, 
inflammation, differentiation, cell death [9]) and it has 
been shown that PARP-1 inhibition targets hypoxia-
mediated repair defects in tumor cells [10] and it reduces 
vasculogenic mimicry [11]. Also, many current generation 
PARP-1 inhibitors carry a nicotinamide-related structure 
that can lead to vasodilation which may potentially 
improve the radiation response [6]. Additionally, we have 
shown that hypoxia can lead to decreased HRR in vitro 
leading to an acquired “BRCAness” which translated into 
increased sensitivity to PARP-1 inhibition in hypoxic 
tumour cells. This “contextual” synthetic lethality as the 
tumour cell kill in vitro was associated with an effect 
of the microenvironment rather than an innate genetic 
susceptibility, per se. However, whether the effect of 
prolonged PARP-1 inhibitor exposure leads to a reciprocal 
modification of the tumour microenvironment has not 
been studied.
Genetically-engineered syngeneic mouse models 
(GEMM) are useful to study the effects of cancer 
treatment within a complex tumour microenvironment 
given the intact immune system and the presence of 
syngeneic host vasculature and stroma. In this study, 
we report the effects of neoadjuvant olaparib prior to 
radiotherapy in a BRCAwt/p53null breast cancer GEMM. 
We show that repetitive olaparib exposure alone can result 
in a significantly decreased hypoxic fraction and increased 
tumor vascular density. These changes contributed to an 
improved radiation response that is independent from 
the inhibitory effects on the repair of exogenous DNA 
damage.
RESULTS
Neoadjuvant olaparib increases growth delay in 
irradiated tumors
Previously it has been shown that interference with 
DNA repair caused by PARP-1 inhibitors can result in 
radiosensitization of tumor cells when given concurrently 
with radiation in vitro and in vivo [12-14]. In addition, 
the vasodilatative effect of olaparib and the reduction of 
the vascular mimicry may be a further mechanism for 
increased radioresponse [6, 11]. However, in this study, 
we wished to determine whether repetitive administration 
of a PARP-1 inhibitor (olaparib) prior to radiotherapy 
(i.e. strictly neoadjuvant, rather than concurrent, olaparib 
treatment) could improve tumour oxygenation prior 
to radiation treatment. We first investigated whether 
neoadjuvant olaparib would increase tumour growth delay 
following a drug-wash out prior to irradiation in vivo. We 
observed that tumor growth was not affected when the 
mice were treated with 50mg/kg BID i.p. olaparib for 6 or 
7 days (Figure 1 and Supplementary Figure 1).
However, tumours treated purely neoadjuvantly with 
olaparib had significantly increased growth delay when 
followed by single dose radiotherapy (12 Gy) as compared 
Figure 1: Growth curves of mice treated with vehicle (grey square), Olaparib alone (6-7 days, 50mg/kg, BID, i. p.) 
(black triangle), radiotherapy (RT) (grey triangle) alone (1 X 12 Gy) and Olaparib (6-7 days, 50mg/kg, BID, i.p.) 
followed by RT (1 X 12 Gy) (black diamond).
Oncotarget87640www.impactjournals.com/oncotarget
to the growth delay following radiotherapy alone (p<0.05) 
(Figure 1).
As PARP-1 inhibitors can inhibit the repair of 
exogenous DNA damage when given concurrently with 
radiotherapy (RT), we tested whether the improved growth 
delay with neoadjuvant olaparib treatment was dependent 
or independent of DNA repair inhibition. First, we used a 
48h time interval between the last olaparib administration 
and radiotherapy as a wash-out period that previously led 
to undetectable olaparib drug levels in our GEMM breast 
cancer model [15]. Second, we measured the increase of 
PAR levels 48 hours after the last olaparib administration. 
For this, we exposed the tumors to intra-tumoral 
injection of H2O2, a potent single strand damaging agent 
(provoking PARylation) that activates PAR, as a positive 
control in vivo. When olaparib was administered to the 
mice 30 minutes prior to H2O2 injection, no tumour 
increase in PAR was observed. In contrast, following the 
48h olaparib washout period, H2O2 treatment increased 
PAR levels significantly, and we did not observe a 
difference in PAR levels in olaparib-treated tumors 
compared to sham-injected control tumors (Figure 2). We 
therefore conclude that the observed increases in tumour 
growth delay was not caused by inhibition of PARylation 
by olaparib during subsequent radiation treatment.
Tumour clonogen kill following neoadjuvant 
olaparib and RT is dependent on the 
microenvironment
To evaluate whether the improved irradiation 
response was caused by the microenvironment we 
compared the tumour clonogen cell kill after either in 
situ irradiation or ex vivo irradiation. After the in situ 
irradiation the tumors were harvested and plated for 
evaluation of clonogenic cell kill and for the ex vivo 
irradiation the tumors were first harvested and irradiated 
after plating the single cell suspension. Tumour clonogenic 
cell kill was only increased in neoadjuvantly olaparib 
treated tumors when the irradiation was performed in vivo 
(Figure 3A) and was not observed when the irradiation 
was given ex vivo (Figure 3B). In other words, excluding 
the tumour microenvironment effect before irradiation 
prevented the effect of neoadjuvant olaparib treatment. We 
conclude that the observed increase in tumor growth delay 
was therefore dependent on the olaparib-induced changes 
on the microenvironment.
Decreased hypoxic fraction in tumors following 
olaparib treatment
To evaluate the oxygenation status of the tumors the 
hypoxia tracer, EF5, was injected i.p. before harvesting 
the tumors (see materials and methods). To ensure a 
robust comparison, we also analysed the necrotic and 
normal tissue within the tumors (see materials and 
methods). The tumors were harvested 48 hours after the 
last olaparib injection to prevent any acute vasodilatation 
effect [6]. Quantification of the EF5 staining revealed that 
the hypoxic fraction in the neoadjuvant olaparib treated 
tumors was lower than the untreated control (Figure 4A). 
Quantification of CD31 staining revealed a higher density 
of vessels in the tumor tissue of the olaparib treated 
tumors (Figure 4B), this difference was not seen in the 
stromal tissue (Supplementary Figure 2). The improved 
oxygenation of the neoadjuvantly treated tumors resulted 
in more irradiation induced DNA damage as quantified 
by phosphorylated 53BP1 (p53BP1) at 1 hour (p=0.04) 
and 6 hours (p=0.02) post radiotherapy (Supplementary 
Figure 3). To exclude pre-existing DNA damage before 
radiotherapy we quantified the p53BP1 foci between 
control tumors and neoadjuvantly treated tumors at 48 
hours following the last olaparib treatment (prior to 
radiotherapy). We did not observe increased p53BP1 foci 
before radiotherapy supporting the similar clonogenic cell 
kill between the control and the unirradiated neoadjuvantly 
treated tumors (Supplementary Figure 3). Similar to our 
previous finding that hypoxia leads to increased sensitivity 
to PARP-1 inhibition in hypoxic tumour cells (due to 
decreased HRR) [10], in this tumor model we observed an 
increased Caspase 3 expression in hypoxic regions after 
olaparib treatment (Supplementary Figure 4).
DISCUSSION
In this study, we show a unique effect in that 
neoadjuvant PARP inhibitor olaparib had a major and 
permanent impact on the microenvironment leading to 
improved oxygenation and therefore, increased clonogen 
cell kill following radiotherapy. Targeted therapies are 
developed to treat cancer with better selectivity and 
efficacy in preselected patient cohorts. One of those 
promising strategies used genetic synthetic lethality 
with the inhibition of the enzyme poly (ADP-ribose) 
polymerase (PARP) by small molecule inhibitors 
in tumors which have a defect in the homologous 
recombination pathway, most characteristically due 
to BRCA mutations [16, 17]. One of the proposed 
mechanisms for our observation using neoadjuvant 
olaparib is that this manoeuvre takes advantage of a 
concept called contextual synthetic lethality whereby 
hypoxia decreased the translation and function of HR 
in hypoxic clonogens and thereby making them more 
sensitive to PARP inhibition [10]. A decreased number of 
tumor clonogens at the time of radiotherapy would lead 
to enhanced overall clonogen kill and increased growth 
delay. This mechanism was supported by the higher 
Caspase 3 activity in the hypoxic regions of the olaparib 
treated tumor compared to the control tumor. Because the 
fraction of hypoxic cells in our fast proliferative tumors 
is small come we didn’t expect this to affect the growth 
rate.
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Olaparib has recently been approved for ovarian 
cancer therapy by the FDA (in 4th line) and European 
commission (platinum sensitive) to treat patients with 
ovarian cancer resulting from hereditary BRCA1 
or BRCA2 mutations. Clinical trials for olaparib in 
combination with radiotherapy are underway (e.g. 
clinical trials for toxicity and the efficacy of olaparib in 
combination with radiation in lung, head and neck and 
breast cancers [8]) after pre-clinical research showed 
an enhanced radiation response that was correlated 
to the inhibition of the DNA damage repair pathway 
by olaparib. [12, 18, 19]. We believe that our data 
in a clinically relevant model now supports clinical 
trials where olaparib is given neoadjuvantly before 
radiotherapy.
PARP-1 is important for the recognition of this 
DNA damage, and binds to DNA strand breaks. Once 
DNA-bound, PARP-1 becomes catalytically activated 
synthesizing PAR polymers onto itself and other 
repair factors (i.e. PARylation). As a result, repair 
proteins such as XRCC1 and DNA polymerase β (pol 
β) are more efficiently and rapidly recruited to sites of 
DNA damage. In the presence of an inhibitor, PARP-1 
still binds to sites of DNA damage, but PARylation is 
prevented enhancing radiotherapy induced cell death. 
Importantly, in our study we did see that the PARylation 
was equal in the control tumors and the neoadjuvant 
olaparib treated tumors after DNA damage induction. 
Alternatively, PARP inhibitors potentiate the cytotoxicity 
of DNA damaging therapies by trapping PARP1 at the 
DNA damage site, a DNA damage repair inhibitory 
process that is not reflected by our PARylation assay. 
PARP trapping occurring after treatment has been 
studied (up to 4 hours) after concurrent administration 
of PARP inhibitors with DNA damaging agents [20-22]. 
Importantly, in our treatment setup in which the DNA 
damaging agent (i.e. radiotherapy) is given 48 hours 
after the last administration of olaparib (i.e. no drugs is 
Figure 2: PARP activity as measured by PAR levels in three independent tumors per cohort. Tumors were treated with or 
without H2O2 as indicated and with or without olaparib as indicated. PAR levels were increased after H2O2 injection. This increase was 
inhibited when olaparib was administered 30 minutes before H2O2 injection. However, if the mice were treated for 6 or 7 days with BID, 
50mg/kg ip olaparib whereby the last administration was given 48 hours before the injection of H2O2, the PAR levels were not affected. 
No statistical difference were observed between the Control and Neoadjuvantly treated animals.
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available in the tumor [15]) we reasonably assume that 
PARP trapping cannot significantly contribute to the 
observed increased irradiation in this rapid proliferative 
tumor. In other words, the differences we observed were 
unlikely due to inhibition of PARylation dependent DNA 
repair machinery.
Hypoxia is a negative prognostic and predictive 
factor contributing to chemoresistance, radioresistance, 
angiogenesis, vasculogenesis, invasiveness, metastasis, 
resistance to cell death, altered metabolism, and 
genomic instability [23]. Many of the molecular 
responses of hypoxia are understood but nevertheless 
targeting of the hypoxic subpopulation of the tumor is 
difficult. Olaparib is, as most other recent developed 
PARP inhibitors, structurally related to nicotinamide. 
Nicotinamide was one of the components of the 
ARCON treatment strategy (accelerated radiotherapy, 
carbogen and nicotinamide) with vasodilatative effect 
targeting tumor hypoxia by preventing intermittent 
vascular, but this strategy was never widely introduced 
[24]. The vasorelaxant effect of olaparib is more potent 
than nicotinamide but the vascular effect of prolonged 
olaparib exposure is not known. The washout period we 
used of 48 hours excluded a direct vasodilatative effect 
due to the nicotinamide related structure of olaparib 
at the time of radiotherapy. We did show however that 
olaparib has a permanent effect on the tumor vessel 
density improving the oxygenation of the tumor. The 
effect of PARP-1 on the angiogenesis has been studied 
but with conflicting results. The most recent study of 
Caldini et al [25] observed that a low concentration of 
PARP inhibitor (3ABA) stimulated angiogenesis by 
decreasing the fibrinolytic activity. On the other hand 
some groups published contrary data. For example 
the group of Graziani investigated the angiogenesis in 
a PARP-1 knock-out mice using an in vivo matrigel 
plug assay and observed that the PARP inhibitor GPI 
15427 hampered formation of tubule-like networks and 
impaired angiogenesis [26]. Importantly, clinical trials 
studying the anti-tumor effect of anti-angiogenesis 
agents as single agent have been negative in contrast 
to the clinical studies using combinations of anti-
angiogenesis with chemotherapy of radiotherapy [27]. 
This has been explained by the observation that anti-
Figure 3: Influence of the tumor microenvironment on radiation response. (A) Tumors were treated with vehicle (control) or 
olaparib (6 or 7 days, 50mg/kg, BID, ip) in vivo followed by mock irradiation or one fraction of 12 Gy. Twenty-four hours later tumors were 
harvested and plated as single cell suspension. Clonogenic survival was analyzed on the 11th day after plating with an increased clonogenic 
cell kill in the neoadjuvantly treated tumors. (B) Tumors were treated with vehicle (control) or olaparib (6 or 7 days, 50mg/kg, BID, ip) in 
vivo followed by harvesting, plating and in vitro mock or 12 Gy dose of radiation. There was no significant difference in radiation response 
between the control and neoadjuvantly treated tumors 11 days after plating.
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angiogenesis treatment resulted in a “normalization” 
of the tumor vasculature, or a decreasing vasculogenic 
mimicry (VM) (which is a process independent of 
angiogenesis). VM was described in 1999 by Maniotis 
et al [28] in highly aggressive and metastatic melanoma 
cells as a form of highly patterned vascular channels 
externally lined by tumor cells, without the existence of 
endothelial cells. Rodriquez et al [11] showed that PARP 
inhibition is also involved in the process of epithelial-
mesenchymal transition (EMT) [29] which is a known 
factor involved in radioresistance [30] and reduced VM. 
We indeed observed that the average vessel size indeed 
increased in the tumors but not in the stromal tissue 
after neoadjuvant treatment with olaparib although we 
Figure 4: (A) The percentage of cells which are EF5 positive (i. e. red regions are hypoxic in Figure 4C) is significantly lower following 
neoadjuvant Olaparib treatment (black diamonds) when compared to the untreated control tumors (grey triangles). (B) The vessel density 
in olaparib (black diamonds) treated and control tumors (grey triangles) are different in the oxic regions within the tumor. (C) Hypoxic 
(positive EF5) area indicated by the white triangle and CD31 (vessel) is indicated by the white arrow. (D) I. Two H&E staining slides of 
a control (left) and neoadjuvantly (right) treated tumor of about 9 mm in length (scale bar of 1 mm is picture in the left top corner). H&E 
staining was executed to discriminate the different tissue types in the tumor. II. Discrimination: orange=tumor tissue, blue=necrotic tissue, 
green=normal breast tissue, brown=artefact, grey=mesenchymal tissue. III. EF5 staining of a control (left) and neoadjuvantly (right) treated 
tumor.
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could not confirm EMT in our model (Supplementary 
Figure 5). This result shows that the repetitive exposure 
of PARP-1 inhibition indeed improved the vascular 
structure specifically in tumors
In conclusion we observed a significant increase 
in radiotherapy response if olaparib was given in a 
neoadjuvant treatment schedule in a HRR proficient, 
immune-competent and clinically relevant tumor model. 
This effect was correlated with improved oxygenation 




Mammary tumors were generated in K14cre;p53F/F 
mice, genotyped, and orthotopically transplanted into 
syngeneic wild-type mice as previously described [15, 31]. 
The onset of tumor growth was checked at least 3 times 
per week starting a week after tumor grafting. Mammary 
tumor size was determined by caliper measurements 
(length and width in millimeters) and tumor volume 
(in mm3) was calculated by using the formula: 1/2 X 
(length X width2). Animals were sacrificed when the 
tumor volume reached 1,500 mm3. All experimental 
procedures on animals were approved by the Animal 
Ethics Committee at the Princess Margaret Cancer Centre.
In vivo treatment schedule
Olaparib (AZD2281) was prepared by diluting 50 
mg/ml stocks in DMSO with 10% 2-hydroxyl-propyl-
beta-cyclodextrine/PBS such that the final volume 
administered by i.p. injection was 10 L/g of body weight. 
The treatment was started when the tumor size reached 
3-4 mm in dimension and was continued for 6 to 7 days 
bi-daily (BID). The tumors were irradiated with a single 
fraction of 12Gy by two orthogonal fields on a small 
animal dedicated high precision image-guided irradiator 
48 hours after the last drug treatment [14].
Clonogenic survival assay
Tumors were harvested and cut into small pieces 
and digested into single cell suspensions in collagenase 
IV (Gibco) and hyaluronidase (Sigma) in DMEM/F12 
media. The cells were counted with trypan blue using a 
hemocytometer. Soft agar colony formation assay was 
used to analyze anchorage-independent cell growth. 
Plates were pre-coated with 0.6% agar diluted in DMEM/
F12 media. Cells were diluted in 0.2% agar and plated in 
triplicates in 24-well plates. The plates were kept in a 5% 
CO2, 3% O2 and 37°C humidified incubator. MTT (3-(4, 
5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) 
was added on the 11th day following plating and the cells 
were incubated overnight for staining. The cells were then 
imaged with a tissue dissection microscope and colonies 
greater than 100 μm in diameter were counted using the 
ImagePro software.
PARP activity assay
PARP activity was indirectly measured by poly-
ADP-ribose (PAR) levels using the HT PARP in vivo 
Pharmacodynamic Assay II kit (Trevigen) as previously 
described [32]. After intratumoral injection of hydrogen 
peroxide (H2O2), tumors were harvested and immediately 
snap frozen. Frozen tumors were lysed, sonicated and 
treated with 1% SDS. The protein concentration of tumor 
lysates was measured using a BCA protein assay. Tumor 
lysates and PAR standards were incubated overnight 
in wells pre-coated with anti-PAR monoclonal capture 
antibody. The wells were later incubated with a polyclonal 
rabbit PAR detecting antibody for 2 hours and then with a 
goat anti-rabbit IgG-HRP secondary antibody for 1 hour. A 
chemiluminescent HRP substrate was added immediately 
before readings as per manufacturer’s instructions. PAR 
values were calculated using relative light units of the 
PAR standards that directly correlate with the amount of 
cellular PAR levels.
Pathology staining
Tumors were harvested and fixed in 10% neutral 
buffered formalin for 24 hours at room temperature and 
then replaced with 75% alcohol. Tumors were processed 
in a conventional tissue processor and embedded into 
paraffin wax using graded alcohol, xylene and paraffin 
wax. Serial sections of 5 μm were cut from the paraffin 
embedded tumor blocks for immunohistochemical 
analyses.
For hypoxia and proliferation analysis, mice were 
injected i.p. with 2-nitroimidazol hypoxia marker EF5 (30 
mg/kg) and active DNA synthesis marker EdU (10 mM), 
respectively, 2.5 hours prior to sacrifice. For EdU staining 
the Click-iT cocktail was applied for 30 min at room 
temperature. Primary antibodies used were as follows: 
PECAM-1 (Santa Cruz sc-1506), Cleaved Caspase-3 
(Cell Signalling), 53BP1Ser1778 (Cell Signalling), Vimentin 
(Fitzgerald 20R-VP004), E-cadherin (BD Biosciences).
Secondary antibodies were: Alexa Fluor 488 
Donkey Anti-Rabbit (Life Technologies), Biotin-Goat 
Anti-Guinea Pig IgG (Jackson ImmunoResearch), Biotin-
Goat Anti-Mouse IgG (Invitrogen)
Images were acquired using an Olympus IX81 
Spinning Disk Confocal Microscope using an PlanApo 
60x/1.42 oil objective lens. A minimum of 50 cells were 
imaged for 53BP1Ser1778 analysis. Images were processed 
and analyzed using ImagePro Plus.
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Pathology analysis
Slides were scanned using a Tissuescope (TS4000) 
laser scanning system for immunofluorescent and H&E 
brightfield images. Images were split into individual 8 bit 
grey scale images using Image ProPlus. Grey scale images 
were loaded onto Definiens Tissue Studio for analysis. 
Regions of interest including tumor, necrosis, stroma, 
artifacts, EF5, empty space and margins were detected by 
creating a training ruleset. Cellular analysis was performed 
by nuclei detection whereby the mean intensity of nuclei 
in each grey channel was measured and the average mean 
intensity was calculated among the pool of samples. 
Subsequently, the threshold was calculated by the average 
mean intensity plus two standard deviations.
Statistics analysis
GraphPad Prism 5.0 was used for statistical 
comparison between 2 groups usinga Mann-Whitney rank 
test. All data were expressed as mean with the standard 
deviation (SD) or standard error of the mean (SEM) as 
indicated.
Abbreviations
 ARCON accelerated radiotherapy, carbogen and 
nicotinamide
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